Apixaban

Deep Vein Thrombosis, Arthroplasty, Pulmonary Embolism + 8 more

Treatment

16 FDA approvals

20 Active Studies for Apixaban

What is Apixaban

Apixaban

The Generic name of this drug

Treatment Summary

Apixaban (brand name Eliquis) is a medication taken by mouth to prevent and treat blood clots. Apixaban works by blocking a substance in the body called factor Xa, which helps reduce the risk of thromboembolic diseases. It was approved by the FDA in 2012.

Eliquis

is the brand name

image of different drug pills on a surface

Apixaban Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Eliquis

Apixaban

2012

15

Approved as Treatment by the FDA

Apixaban, otherwise known as Eliquis, is approved by the FDA for 16 uses which include Deep Vein Thrombosis and Prophylaxis of Deep Vein Thrombosis .

Deep Vein Thrombosis

Prophylaxis of Deep Vein Thrombosis

Deep vein thrombosis recurrent

Non Valvular Atrial Fibrillation (nv AF)

Recurrent Pulmonary Embolism (Disorder)

Arthroplasty

recurrent Prophylaxis of Deep Vein Thrombosis

Deep Vein Thrombosis

Total Knee Arthroplasty

Stroke

Atrial Fibrillation

Systemic Embolism

Pulmonary Embolism

Disease

Pulmonary Embolism

Deep Vein Thrombosis

Effectiveness

How Apixaban Affects Patients

Apixaban stops the activation of certain proteins that help form a blood clot. It does this by blocking the free and bound forms of factor Xa and prothrominase, preventing clots from forming.

How Apixaban works in the body

Apixaban works to prevent blood clots by blocking the action of an enzyme called factor Xa. It also limits the production of another enzyme, prothrominase, which helps form clots. By inhibiting these enzymes, apixaban helps keep the blood from clotting.

When to interrupt dosage

The recommended measure of Apixaban is contingent upon the diagnosed condition, including Deep Vein Thrombosis (DVT), Deep Vein Thrombosis and Arthroplasty. The amount of dosage is contingent upon the technique of administration (e.g. Oral or Tablet, film coated - Oral) outlined in the following table.

Condition

Dosage

Administration

Deep Vein Thrombosis

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Pulmonary Embolism

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Atrial Fibrillation

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Disease

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Deep Vein Thrombosis

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Stroke

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

recurrent Prophylaxis of Deep Vein Thrombosis

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Total Knee Arthroplasty

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Systemic Embolism

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Arthroplasty

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Pulmonary Embolism

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Warnings

Apixaban Contraindications

Condition

Risk Level

Notes

Hemorrhage

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Apixaban may interact with Pulse Frequency

There are 20 known major drug interactions with Apixaban.

Common Apixaban Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

Apixaban may increase the anticoagulant activities of (R)-warfarin.

(S)-Warfarin

Major

Apixaban may increase the anticoagulant activities of (S)-Warfarin.

4-hydroxycoumarin

Major

Apixaban may increase the anticoagulant activities of 4-hydroxycoumarin.

Abciximab

Major

Apixaban may increase the anticoagulant activities of Abciximab.

Acenocoumarol

Major

Apixaban may increase the anticoagulant activities of Acenocoumarol.

Apixaban Toxicity & Overdose Risk

Animal studies suggest a higher risk of maternal bleeding, but no increase in fetal malformations or deaths. It is unknown if this applies to humans, so it should only be used if the benefits outweigh the risks. There is not enough information to determine if it is safe and effective for labor and birth. Animal studies suggest that it can be excreted in milk, so nursing mothers should consider stopping breastfeeding or taking apixaban. Safety and effectiveness in pediatric and geriatric patients has not been studied yet. Patients with end stage renal disease may have different reactions to apixaban, but no dosage adjustments are necessary for mild hepatic impairment

image of a doctor in a lab doing drug, clinical research

Apixaban Novel Uses: Which Conditions Have a Clinical Trial Featuring Apixaban?

83 active trials are analyzing the potential of Apixaban to ameliorate Deep Vein Thrombosis (DVT), Stroke and Pulmonary Embolism.

Condition

Clinical Trials

Trial Phases

Pulmonary Embolism

22 Actively Recruiting

Early Phase 1, Phase 4, Phase 3, Not Applicable

Total Knee Arthroplasty

6 Actively Recruiting

Not Applicable, Phase 2, Phase 3

recurrent Prophylaxis of Deep Vein Thrombosis

0 Actively Recruiting

Atrial Fibrillation

2 Actively Recruiting

Not Applicable

Deep Vein Thrombosis

0 Actively Recruiting

Deep Vein Thrombosis

9 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 4

Disease

0 Actively Recruiting

Arthroplasty

3 Actively Recruiting

Not Applicable

Stroke

6 Actively Recruiting

Not Applicable, Phase 1

Pulmonary Embolism

0 Actively Recruiting

Systemic Embolism

2 Actively Recruiting

Not Applicable

Apixaban Reviews: What are patients saying about Apixaban?

5

Patient Review

4/27/2017

Apixaban for Blood Clot in a Deep Vein

This was easy to take and I didn't experience any side effects after my body adjusted. I did have a few headaches at first, but they quickly dissipated.

5

Patient Review

1/5/2014

Apixaban for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

I was unable to take Pradaxa due to the bleeding it caused, but this other drug has been working great for me.

5

Patient Review

5/21/2017

Apixaban for Blood Clot in Lung

I took one 5mg tablet twice a day as directed, and I noticed zero negative side effects. This is much better than Warfarin for me, which left me feeling disoriented, clumsy, and with constant headaches.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about apixaban

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is apixaban and Eliquis the same thing?

"Eliquis is an anticoagulant that works by stopping the enzyme complex factor Xa from working. This reduces the likelihood of blood clots forming in the body, and therefore reduces the risk of a stroke or heart attack."

Answered by AI

What should I avoid when taking apixaban?

"There is some evidence that taking ginger, ginkgo biloba, turmeric, or certain Chinese herbs along with a blood-thinning medication like apixaban may increase the risk of bleeding. Also, St. John's wort may make apixaban less effective."

Answered by AI

What are side effects of apixaban?

"The following are symptoms of something serious: bleeding gums, nosebleeds, heavy vaginal bleeding, red, pink, or brown urine, red or black, tarry stools, coughing up or vomiting blood or material that looks like coffee grounds, swelling or joint pain, headache."

Answered by AI

What is apixaban drug used for?

"UK

Apixaban is a medicine that helps to prevent blood clots. It is used to treat people with atrial fibrillation (a heart condition that can cause an irregular heart beat) and to prevent stroke."

Answered by AI

Is Eliquis and apixaban the same?

"Eliquis is an anticoagulant that works by stopping an enzyme complex called factor Xa. This prevents blood clots from forming in your body, so you're less likely to have a stroke or heart attack."

Answered by AI

Clinical Trials for Apixaban

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Have you considered Apixaban clinical trials?

We made a collection of clinical trials featuring Apixaban, we think they might fit your search criteria.
Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Portable Dynamic Chest X-Ray for ICU Patients

18+
All Sexes
Boston, MA

Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU. The goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care. Participants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Gyorgy Frendl, MD PhD

Have you considered Apixaban clinical trials?

We made a collection of clinical trials featuring Apixaban, we think they might fit your search criteria.
Go to Trials
Image of RUSH University Medical Center in Chicago, United States.

Thrombolysis/Thrombectomy for Deep Vein Thrombosis

18 - 75
All Sexes
Chicago, IL

The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.

Phase 4
Waitlist Available

RUSH University Medical Center

Bulent Arslan, MD

Image of Medical University of South Carolina in Charleston, United States.

Education + Decision Support for Blood Clots After Cancer Surgery

18+
All Sexes
Charleston, SC

While blood clots after major cancer surgery are common and harmful to patients, the medications to decrease blood clot risk are seldom used after patients leave the hospital despite the recommendation of multiple professional medical societies. The reason why these medications are seldom prescribed is not well understood. The main questions this study aims to answer are: * Does surgeon education paired with an electronic medical record based decision support tool improve the guideline concordant prescription of pharmacologic venous thromboembolism after abdominopelvic cancer surgery? * Does dedicated patient education regarding blood clots at the time of hospital discharge after abdominopelvic cancer surgery improve understanding of the risk of venous thromboembolism and adherence to pharmacologic prophylaxis? The investigators will study these questions using a stepped-wedge randomized trial where groups of surgeons will use a tool integrated to the electronic medical record to educate them on the individualized patient risks of blood clots after major cancer surgery and inform them regarding guidelines for preventative medicines. Utilization of the medications before and after using the tool will be compared. Patients will be administered a questionnaire assessing their awareness of blood clots as a risk after cancer surgery. For those prescribed medications to reduce blood clot risk after leaving the hospital, the questionnaire will evaluate whether they took the medications as prescribed. Survey results will be evaluated before and after implementation of education on blood clot risk at the time of hospital discharge.

Recruiting
Has No Placebo

Medical University of South Carolina

Thomas Curran, MD MPH

Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Have you considered Apixaban clinical trials?

We made a collection of clinical trials featuring Apixaban, we think they might fit your search criteria.
Go to Trials